As cars get heavier, bigger, and more powerful, aerodynamic aids are becoming increasingly necessary, along with bigger ...

Investors have been buying up struggling companies in the hope of a relief rally. But Matthew Brooks says they’re too early ...

It still needs to rebuild trust, but lower expectations and several recovery levers make the shares worth considering. The ...

CSL shares have been hammered by earnings disappointments. But the long-term investment case remains strong. You’re reading a free article with opinions that may differ from The Motley Fool’s Premium ...

In a 90-day review, CSL told the market it would take another $US5bn ($A6.9bn) non-cash impairment. The first $1.5bn of this was recognised during the first-half ...

CSL has slashed its revenue projection for the fiscal year from $15.8 billion to $15.2 billion, in another indication of the Australian company’s financial distress since its ill-fated 2022 ...

CSL has lost the trust of major investors after slashing earnings forecasts reaffirmed three months ago and announcing one of the biggest write-downs in Australian corporate history as the healthcare ...

Shares in health giant CSL tanked today, with the stock closing 16 per cent lower, at $100.75. At earlier points in the session, the stock was down more than 20 per cent, sinking below $100 to decade ...

CSL trades at a discount despite owning a dominant, hard-to-replicate global plasma-derived therapies infrastructure. Transformation Program targets $500–$550M in annual pre-tax cost reductions by ...

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. CSL (ASX:CSL) has outlined a restructuring plan that ...

Business remains robust and brokers see ASX stock soaring up to 100%. You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley ...